PCS
RNAC icon

Personal CFO Solutions’s Cartesian Therapeutics RNAC Stock Holding History

Personal CFO Solutions’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,696
Closed -$35.1K – 574
2023
Q4 		$35.1K Sell
1,696
-134
-7% -$4K 0.01% 510
2023
Q3 		$58.2K Sell
1,830
-1,000
-35% -$33.4K 0.01% 450
2023
Q2 		$95.1K Hold
2,830
– – 0.02% 461
2023
Q1 		$118K Hold
2,830
– – 0.02% 459
2022
Q4 		$95.9K Sell
2,830
-33
-1% -$1.4K 0.02% 444
2022
Q3 		$141K Buy
2,863
+500
+21% +$27.5K 0.04% 394
2022
Q2 		$93K Sell
2,363
-133
-5% -$3.94K 0.02% 413
2022
Q1 		$92K Buy
2,496
+650
+35% +$40.7K 0.02% 452
2021
Q4 		$181K Buy
1,846
+401
+28% +$43.1K 0.03% 454
2021
Q3 		$180K Buy
1,445
+476
+49% +$57.5K 0.04% 425
2021
Q2 		$122K Buy
+969
New +$115K 0.03% 420

Other funds holding RNAC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Personal CFO Solutions's RNAC Position: Q1 2024 in Review

Personal CFO Solutions sold out of Cartesian Therapeutics (RNAC) in Q1 2024, closing a stake of 1,696 shares — an estimated $35.1K sold.

Personal CFO Solutions first reported a position in RNAC in Q2 2021 and held it in 11 quarters. The position peaked at $181K in Q4 2021. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

  • Personal CFO Solutions reported no remaining Cartesian Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Personal CFO Solutions sold 1,696 Cartesian Therapeutics shares in Q1 2024, an estimated $35.1K.
  • Personal CFO Solutions first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 11 quarters.
  • Personal CFO Solutions's Cartesian Therapeutics position peaked at $181K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Personal CFO Solutions's 13F filing for Q1 2024, filed 13 May 2024.